AN2 Therapeutics (ANTX) director receives 3,775-share fully vested grant

Rhea-AI Filing Summary

Marks Gilbert Lynn reported acquisition or exercise transactions in this Form 4 filing.

AN2 Therapeutics director Gilbert Lynn Marks received a stock grant of 3,775 shares of Common Stock on April 10, 2026. The shares were issued in lieu of cash under the company’s non-employee director compensation policy and carry a grant price of $0.00 per share.

All 3,775 shares vest immediately, meaning Marks has full ownership without a vesting schedule. Following this award, he directly holds a total of 79,084 shares of AN2 Therapeutics common stock. This is a compensation-related grant, not an open-market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Marks Gilbert Lynn

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,775	$0.00	--

Holdings After Transaction: Common Stock — 79,084 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Shares granted: 3,775 shares Grant price: $0.00 per share Shares after transaction: 79,084 shares +2 more

5 metrics

Shares granted 3,775 shares Common Stock grant on April 10, 2026

Grant price $0.00 per share Equity compensation in lieu of cash

Shares after transaction 79,084 shares Total Common Stock directly held after grant

Transaction code A (Grant, award, or other acquisition) Non-derivative Common Stock acquisition

Vesting terms Immediate vesting All granted shares vest immediately upon issuance

Key Terms

non-employee director compensation policy, vest immediately, Common Stock, Grant, award, or other acquisition

4 terms

non-employee director compensation policy financial

"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy."

vest immediately financial

"All shares vest immediately."

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition regulatory

"transaction_code_description: "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Marks Gilbert Lynn

(Last) (First) (Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/10/2026		A		3,775(1)	A	$0	79,084	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.

	/s/ Lucy Day, Attorney-in-Fact for Gilbert Lynn Marks	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did AN2 Therapeutics (ANTX) report for Gilbert Lynn Marks?

AN2 Therapeutics reported that director Gilbert Lynn Marks received a grant of 3,775 shares of Common Stock. The award was issued as equity compensation instead of cash under the non-employee director compensation policy and is recorded as a Form 4 acquisition.

Was the AN2 Therapeutics (ANTX) insider transaction an open-market buy or a stock grant?

The transaction was a stock grant, not an open-market purchase. Director Gilbert Lynn Marks acquired 3,775 shares at $0.00 per share as compensation in lieu of cash, consistent with the company’s non-employee director compensation policy.

How many AN2 Therapeutics (ANTX) shares does Gilbert Lynn Marks hold after this grant?

After receiving the 3,775-share grant, Gilbert Lynn Marks directly holds 79,084 shares of AN2 Therapeutics Common Stock. This total reflects his position immediately following the compensation-related award reported in the Form 4 filing for April 10, 2026.

Do the new AN2 Therapeutics (ANTX) shares granted to Gilbert Lynn Marks have a vesting schedule?

The 3,775 AN2 Therapeutics shares granted to Gilbert Lynn Marks vest immediately. According to the disclosure, all shares issued under the non-employee director compensation policy for this transaction are fully vested upon grant, giving him full ownership right away.

Why did AN2 Therapeutics (ANTX) issue shares to Gilbert Lynn Marks at $0.00 per share?

The shares were issued at $0.00 per share because they represent equity compensation, not a market purchase. Under the non-employee director compensation policy, Marks received 3,775 fully vested shares in lieu of cash compensation for his director service.